valproate semisodium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
valproate semisodium: clinical details
Prescribing considerations
- Specialist initiation and supervision are required.
- For new patients younger than 55 years, two specialists must document that no effective or tolerated alternative exists or that reproductive risks do not apply.
- For women and girls able to become pregnant, comply with the Pregnancy Prevention Programme and required risk acknowledgement and review processes.
- Verify the indication and product carefully: selected semisodium products are licensed for bipolar mania, not epilepsy.
- Consider renal impairment, hepatic risk, metabolic disease, bleeding risk, weight gain, interactions and possible hyperammonaemia.
Contraindications and cautions
- Pregnancy for treatment of bipolar disorder
- Women of childbearing potential younger than 55 years unless required specialist decisions and Pregnancy Prevention Programme conditions are fulfilled
- Active liver disease or relevant personal or family history of severe hepatic dysfunction
- Known urea-cycle disorder or porphyria
- Relevant POLG-related mitochondrial disorder
- Uncorrected systemic primary carnitine deficiency
- Hypersensitivity to the active substance or excipients
Monitoring
- Before treatment: body weight or BMI, full blood count, liver function and coagulation screening.
- Monitor body weight or BMI, full blood count and liver function.
- Check full blood count and coagulation after spontaneous bleeding or bruising and before surgery.
- Plasma concentrations are not routinely required but may help assess adherence, suspected toxicity, interactions or unexplained loss of control.
Clinical pharmacology
Valproate semisodium is a stable compound of sodium valproate and valproic acid that dissociates to valproate. It has near-complete oral bioavailability, concentration-dependent protein binding and extensive hepatic metabolism, principally through glucuronidation and beta-oxidation.
Formulation and product differences
- Selected Syonell and Depakote products are gastro-resistant oral tablets containing valproate semisodium.
- Brand, tablet appearance, excipients and sodium content differ; confirm the prescribed product and avoid inadvertent substitution with valproate products licensed for other conditions.
- Gastro-resistant tablets must be swallowed whole rather than crushed or chewed.
valproate semisodium preparations and strengths
Gastro-resistant tablet
Route: Oral
Strengths: 250 mg, 500 mg
Tablet
Route: Oral
Strengths: 250 mg, 500 mg
valproate semisodium interactions
Tell the prescriber or pharmacist about all medicines, supplements and herbal products. Important interactions include:
Carbapenem antibiotics
They can rapidly and substantially lower valproate concentrations, risking loss of effect; combined use should generally be avoided.
Lamotrigine
Valproate increases lamotrigine exposure and toxicity risk, including serious skin reactions.
Warfarin and other coumarin anticoagulants
Valproate may increase anticoagulant effects and bleeding risk.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.